56 endometrial carcinomas cases,56 ovarian cancer case and 56 cases of non-gynecological cancer, were subjected to immunohistochemical (IHC) analysis of SOX17 and PAX8.<h4>Results</h4>In endometrial carcinomas, PAX8-high/SOX17-high co-expression strongly favored endometrioid histology (90% vs. 68.8%, p = 0.04), while ovarian high-grade serous carcinomas commonly expressed PAX8 (78.9% high) with heterogeneous SOX17 expression (47.4% high). Here, PAX8 is linked to endometrial carcinoma.